Her-2/neu test predicts drug response
This article was originally published in The Gray Sheet
Executive Summary
Metastatic breast cancer patients whose serum Her-2/neu levels decrease by less than 20% in response to trastuzumab therapy are unlikely to benefit from the anti-cancer drug, according to a Bayer Diagnostics study. The 307-patient study found that women with a less than 20% reduction in Her-2/neu levels had a shorter duration of response and a decreased overall survival rate. Bayer suggests that the Her-2/neu test could be used as an early predictor of a patient's response to trastuzumab therapy, allowing doctors to optimize treatment regimens...